Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults

NCT04723394 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04723394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04723394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Safety and Efficacy of AZD7442 for the Treatment of COVID-19 in Non-hospitalized Adults
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2021
Completion date
October 19, 2022
Enrollment
910 (actual)
Sites
103

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19